| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | Düzenleyici ortaklık
> Düzenleyici kurumlarla çalışma | 5.000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Hasta savunuculuğu
> Hasta hakları | Düzenleyici ortaklık
> Düzenleyici kurumlarla çalışma | 10.000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Solunum
> Pulmoner fibrozis | Düzenleyici ortaklık
> Düzenleyici kurumlarla çalışma | 1.000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | Nöromüsküler
> Duchenne | Düzenleyici ortaklık
> Sağlık Teknolojisi Değerlendirmesi (HTA) ve geri ödeme incelemelerine katılın | 5.000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | Hasta savunuculuğu
> Hasta hakları | Düzenleyici ortaklık
> Sağlık Teknolojisi Değerlendirmesi (HTA) ve geri ödeme incelemelerine katılın | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Hasta savunuculuğu
> Hasta hakları | Düzenleyici ortaklık
> Sağlık Teknolojisi Değerlendirmesi (HTA) ve geri ödeme incelemelerine katılın | 10.000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | Romatizmal
> Lupus | Düzenleyici ortaklık
> Sağlık Teknolojisi Değerlendirmesi (HTA) ve geri ödeme incelemelerine katılın | 100.000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Hasta savunuculuğu
> Hasta hakları | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | Kanama
> Kanama bozuklukları: çoğu tür | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 5.000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Yaşlı insanlar
> Yaşlı insanlar | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Nadir
> Nadir hastalıklar: metabolik/lizozomal | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 100.000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | Romatizmal
> Romatizmal hastalıklar: çoğu tür | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 10.000 | National | Regularly | 119062924366 |
| Ministry of Health. | Kardiyovasküler
> Kardiyovasküler & kalp rahatsızlıkları | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 5.000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Hasta savunuculuğu
> Hasta hakları | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 10.000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Solunum
> Pulmoner fibrozis | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 1.000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | Kardiyovasküler
> Kardiyovasküler & kalp rahatsızlıkları | Düzenleyici ortaklık
> Diğer sağlık savunucularıyla | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | Gastrointestinal
> Gastrointestinal: diğer | Düzenleyici ortaklık
> Diğer sağlık savunucularıyla | 1.000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | Nadir
> Wilson hastalığı | Düzenleyici ortaklık
> Diğer sağlık savunucularıyla | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | Nadir
> Nadir hastalıklar: genetik | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 1.000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | Hasta güvenliği
> İatrojenik | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 1.000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Çölyak | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 100.000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | Nadir
> Nadir hastalıklar: genetik | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | Karaciğer
> Karaciğer hastalıkları: nakiller | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 5.000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Solunum
> Pulmoner fibrozis | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 1.000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | Nadir
> Nadir hastalıklar: çoğu tür | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 100.000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | Kanama
> Kanama bozuklukları: çoğu tür | Politika ve mevzuatı etkileme
> Kamuoyu dinlemelerine ve istişarelere katılın | 5.000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronik
> Genel olarak kronik hastalıklar | Politika ve mevzuatı etkileme
> Kamuoyu dinlemelerine ve istişarelere katılın | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Çölyak | Politika ve mevzuatı etkileme
> Kamuoyu dinlemelerine ve istişarelere katılın | 100.000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | Nörolojik
> Multipl skleroz | Politika ve mevzuatı etkileme
> Kamuoyu dinlemelerine ve istişarelere katılın | 5.000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Çölyak | Politika ve mevzuatı etkileme
> Parlamenterleri ve siyasi liderleri harekete geçirin | 100.000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Politika ve mevzuatı etkileme
> Parlamenterleri ve siyasi liderleri harekete geçirin | 5.000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | Nadir
> Nadir hastalıklar: genetik | Politika ve mevzuatı etkileme
> Parlamenterleri ve siyasi liderleri harekete geçirin | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | Nadir
> Nadir hastalıklar: genetik | Politika ve mevzuatı etkileme
> Hasta koruma yasa tasarıları ve hakları için savunuculuk yapın | 1.000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Çölyak | Politika ve mevzuatı etkileme
> Halk sağlığı mevzuatının hazırlanmasına katkıda bulunmak | 100.000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Kanser
> Kanser: pankreas | Politika ve mevzuatı etkileme
> Tıbbi bakımdaki engellerin/anormalliklerin giderilmesi | 1.000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Nadir
> Nadir hastalıklar: genetik | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Adil ilaç fiyatlandırması için savunuculuk yapın | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | Solunum
> KOAH | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Adil ilaç fiyatlandırması için savunuculuk yapın | 1.000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronik
> Genel olarak kronik hastalıklar | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Fiyat inceleme kurulu müzakerelerine katılın | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Nadir
> Nadir hastalıklar: genetik | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Fiyat inceleme kurulu müzakerelerine katılın | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Nadir
> Nadir hastalıklar: metabolik/lizozomal | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | Solunum
> Solunum: çoğu durum | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 5.000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | Solunum
> KOAH | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 1.000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Kanser
> Kanser: pankreas | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 1.000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Hasta savunuculuğu
> Hasta hakları | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | Endokrin
> Diyabet (hem tip 1 hem de tip 2) | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 5.000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | Kemik
> Osteoartrit ve Osteoporoz | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 5.000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronik
> Genel olarak kronik hastalıklar | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | Solunum
> KOAH | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 1.000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | Nadir
> Nadir hastalıklar: çoğu tür | Kanıta dayalı hasta girdisi
> Kararları bilgilendirmek için hasta içgörülerini kullanın | 1.000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Hasta savunuculuğu
> Hasta hakları | Kanıta dayalı hasta girdisi
> Kararları bilgilendirmek için hasta içgörülerini kullanın | 10.000 | National | Sometimes | 119073823192 |
| They consult us. | Nörolojik
> Fibromiyalji | Kanıta dayalı hasta girdisi
> Kararları bilgilendirmek için hasta içgörülerini kullanın | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | Nadir
> Nadir hastalıklar: çoğu tür | Kanıta dayalı hasta girdisi
> Düzenleyici kurumlara Gerçek Dünya Kanıtı (RWE) sağlayın | 1.000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | Nadir
> Nadir hastalıklar: çoğu tür | Kanıta dayalı hasta girdisi
> Hasta hikayelerinden ve yaşanmış deneyim anlatılarından yararlanın | 1.000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | Nörodejeneratif
> Alzheimer | Kanıta dayalı hasta girdisi
> Hasta hikayelerinden ve yaşanmış deneyim anlatılarından yararlanın | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronik
> Genel olarak kronik hastalıklar | Kanıta dayalı hasta girdisi
> Kanıtları ve içgörüleri politika girdisine dönüştürün | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | Yaşlı insanlar
> Yaşlı insanlar | Tanı ve ilaç teslimatı
> Güvenli ve etkili ilaç kullanımını sağlayın | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | Nadir
> Von Hippel-Lindau sendromu | Tanı ve ilaç teslimatı
> Güvenli ve etkili ilaç kullanımını sağlayın | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Hasta savunuculuğu
> Hasta hakları | Tanı ve ilaç teslimatı
> Güvenli ve etkili ilaç kullanımını sağlayın | 10.000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | Yaşlı insanlar
> Yaşlı insanlar | Tanı ve ilaç teslimatı
> Klinik kılavuzların geliştirilmesine katılın | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Yaşlı insanlar
> Yaşlı insanlar | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | Kanama
> Hemofili | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | Kardiyovasküler
> Kardiyovasküler & kalp rahatsızlıkları | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | Nadir
> Nadir hastalıklar: çoğu tür | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 1.000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | Nörolojik
> Multipl skleroz | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 5.000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | Nörolojik
> Multipl skleroz | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 10.000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 10.000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 5.000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Hasta savunuculuğu
> Hasta hakları | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 10.000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | Nörolojik
> Nörolojik: çoğu durum | Kurumsal yönetişim
> Kamu yararına veya hayır amaçlı kuruluş olarak resmi statüyü korumak | 1.000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | Kurumsal yönetişim
> Kamu yararına veya hayır amaçlı kuruluş olarak resmi statüyü korumak | 5.000 | Local | Regularly | 119072832940 |
etkileşimler
eylemler & savunuculuk
19 bahsetmeler
